See the published version of this preprint at EJNMMI Radiopharmacy and Chemistry.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Helge Thisgaard
Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark,
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9492-448X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: With increasing clinical demand for gallium-68, commercial germanium-68/gallium-68 ([68Ge]Ge/[68Ga]Ga) generators are incapable of supplying sufficient amounts of the short-lived daughter isotope. In this study, we demonstrate a high-yield, automated method for producing multi-Curie levels of [68Ga]GaCl3 from solid zinc-68 targets and subsequent labelling to produce clinical-grade [68Ga]Ga-PSMA-11 and [68Ga]Ga-DOTATATE.
Results: Enriched zinc-68 targets were irradiated at up to 80 µA with 13 MeV protons for 120 min; repeatedly producing up to 194 GBq (5.24 Ci) of purified gallium-68 in the form of [68Ga]GaCl3 at the end of purification (EOP) from an expected >370 GBq (>10 Ci) at end of bombardment. A fully automated dissolution/separation process was completed in 35 min. Isolated product was analysed according to the draft Ph. Eur. monograph for accelerator produced [68Ga]GaCl3 and found to comply with all specifications. In every instance, the radiochemical purity exceeded 99.9% and importantly, the radionuclidic purity was sufficient to allow for a shelf-life of up to 7 h based on this metric alone. Fully automated production of up to 72.2 GBq [68Ga]Ga-PSMA-11 was performed, providing a product with high radiochemical purity (>98.2%) and very high apparent molar activities of up to 722 MBq/nmol. Further, manual radiolabelling of up to 3.2 GBq DOTATATE was performed in high yields (>95%) and with apparent molar activities (9-25 MBq/nmol) sufficient for clinical use.
Conclusions: We have developed a high-yielding, automated method for the production of very high amounts of [68Ga]GaCl3, sufficient for supply proximal radiopharmacies. The reported method led to record-high purified gallium-68 activities (194 GBq at end of purification) and subsequent labelling of PSMA-11 and DOTATATE. The process was highly automated from irradiation through to formulation of the product, and as such comprised a high level of radiation protection. The quality control results obtained for both [68Ga]GaCl3 for radiolabelling and [68Ga]Ga-PSMA-11 are promising for clinical use.
Keywords
Gallium-68, cyclotron, accelerator, DOTATATE, PSMA-11, solid target, targetry
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at EJNMMI Radiopharmacy and Chemistry.
Version 1
Posted 22 Sep, 2020
No community comments so far
Editorial decision: Minor revision
On 18 Oct, 2020
Review #1 received
Received 02 Oct, 2020
Review #2 received
Received 02 Oct, 2020
Reviewers invited
Invitations sent on 30 Sep, 2020
Reviewer #1 agreed
On 30 Sep, 2020
Reviewer #2 agreed
On 30 Sep, 2020
Editor assigned
On 29 Sep, 2020
Editor invited
On 28 Sep, 2020
Submission checks complete
On 17 Sep, 2020
First submitted
On 16 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Biochemistry
Learn more about our company.
See the published version of this preprint at EJNMMI Radiopharmacy and Chemistry.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Helge Thisgaard
Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark,
Corresponding Author
ORCiD: https://orcid.org/0000-0001-9492-448X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at EJNMMI Radiopharmacy and Chemistry.
Version 1
Posted 22 Sep, 2020
No community comments so far
Editorial decision: Minor revision
On 18 Oct, 2020
Review #1 received
Received 02 Oct, 2020
Review #2 received
Received 02 Oct, 2020
Reviewers invited
Invitations sent on 30 Sep, 2020
Reviewer #1 agreed
On 30 Sep, 2020
Reviewer #2 agreed
On 30 Sep, 2020
Editor assigned
On 29 Sep, 2020
Editor invited
On 28 Sep, 2020
Submission checks complete
On 17 Sep, 2020
First submitted
On 16 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Biochemistry
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at EJNMMI Radiopharmacy and Chemistry.
Background: With increasing clinical demand for gallium-68, commercial germanium-68/gallium-68 ([68Ge]Ge/[68Ga]Ga) generators are incapable of supplying sufficient amounts of the short-lived daughter isotope. In this study, we demonstrate a high-yield, automated method for producing multi-Curie levels of [68Ga]GaCl3 from solid zinc-68 targets and subsequent labelling to produce clinical-grade [68Ga]Ga-PSMA-11 and [68Ga]Ga-DOTATATE.
Results: Enriched zinc-68 targets were irradiated at up to 80 µA with 13 MeV protons for 120 min; repeatedly producing up to 194 GBq (5.24 Ci) of purified gallium-68 in the form of [68Ga]GaCl3 at the end of purification (EOP) from an expected >370 GBq (>10 Ci) at end of bombardment. A fully automated dissolution/separation process was completed in 35 min. Isolated product was analysed according to the draft Ph. Eur. monograph for accelerator produced [68Ga]GaCl3 and found to comply with all specifications. In every instance, the radiochemical purity exceeded 99.9% and importantly, the radionuclidic purity was sufficient to allow for a shelf-life of up to 7 h based on this metric alone. Fully automated production of up to 72.2 GBq [68Ga]Ga-PSMA-11 was performed, providing a product with high radiochemical purity (>98.2%) and very high apparent molar activities of up to 722 MBq/nmol. Further, manual radiolabelling of up to 3.2 GBq DOTATATE was performed in high yields (>95%) and with apparent molar activities (9-25 MBq/nmol) sufficient for clinical use.
Conclusions: We have developed a high-yielding, automated method for the production of very high amounts of [68Ga]GaCl3, sufficient for supply proximal radiopharmacies. The reported method led to record-high purified gallium-68 activities (194 GBq at end of purification) and subsequent labelling of PSMA-11 and DOTATATE. The process was highly automated from irradiation through to formulation of the product, and as such comprised a high level of radiation protection. The quality control results obtained for both [68Ga]GaCl3 for radiolabelling and [68Ga]Ga-PSMA-11 are promising for clinical use.
Figure 1
Figure 2
Figure 3
Loading...